We recently published an article titled Jim Cramer’s Game Plan: 17 Stocks in Focus. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against the other stocks.
On Friday, Jim Cramer, the host of Mad Money, took time to guide investors through this week’s events on Wall Street, drawing attention to earnings reports from various companies, including major players in the tech sector. He also acknowledged the market’s downturn over the past few days, noting the impact of recent developments on investor sentiment.
Cramer specifically pointed out that investors should watch the new home sales report due out this Wednesday. He explained that the housing market has taken a significant hit recently, largely due to a mix of severe weather conditions and, more critically, high mortgage rates. The surge in interest rates has been particularly damaging to homebuilders.
“We need a pickup to verify that housing isn’t just falling off a cliff at this point. I’m actually not hopeful.”
READ ALSO Jim Cramer Discussed These 11 Stocks Recently and Jim Cramer Shed Light on These 10 Stocks
Looking ahead to Thursday, Cramer noted that the first gross domestic product reading of the week would be released, and he expects it to reflect strong performance. He attributed the anticipated strength to a business climate that gained momentum following the election, when many investors began to believe that President Trump’s policies would be more favorable for business than those of his predecessor, President Biden.
On Friday, Cramer also pointed out a noteworthy trend: interest rates had declined, a pattern that had persisted throughout the week. This, according to Cramer, raised the possibility that the upcoming GDP report could be the final strong one before the market adjusts to the changing economic environment. While Cramer clarified that he was not making any definitive predictions, he emphasized that these market movements were indicative of what the market was signaling.
“So let me give you the bottom line: Out of nowhere, the momentum stocks had a hideous downturn today. It’s hurt many aggressive growth investors. Can this pullback finally run its course? I hope so.”
Our Methodology
For this article, we compiled a list of 17 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on February 21. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey’s database of over 1,000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A nurse in a telehealth platform talking with a patient on video call for consultation.
Hims & Hers Health, Inc. (NYSE:HIMS)
Number of Hedge Fund Holders: 38
Cramer highlighted the chatter around whether Hims & Hers Health, Inc. (NYSE:HIMS) will be able to offer cheaper alternatives to GLP-1 drugs.
“Finally, I have to tell you there’s one stock that’s become a true battleground here and I don’t mean Palantir. I’m talking about a stock called Hims & Hers Health. That’s an online healthcare company that currently offers a less expensive alternative to the GLP-1 weight loss drugs as long as they’re relatively unavailable. Now today the FDA said that Novo Nordisk GLP-1 formulation is no longer in short supply, which, which could mean that the compounding pharmacies that are making similar versions of the drug have to stop.
Now Hims & Hers has said it can still make the cheaper version some way, but the market seems skeptical. Hence the stock’s astounding 26% collapse today. But then again, it’s still up more than a 100% year to date so profit-taking… makes sense to me.”
Hims & Hers Health (NYSE:HIMS) offers a telehealth platform that delivers both prescription and over-the-counter health and wellness products and services, such as medication, skincare, sexual health, hair care, and wellness items, along with continuous support from licensed healthcare providers.
Overall HIMS ranks 5th on our list of the stocks Jim Cramer recently talked about. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than HIMS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article was originally published at Insider Monkey.